bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.91 USD
-0.01 (-1.04%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $0.90 -0.01 (-0.55%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
bluebird bio, Inc. [BLUE]
Reports for Purchase
Showing records 401 - 420 ( 532 total )
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Stock Reaction Has No Correlation with Current Data/Program
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
How Will the Rubble Bounce, or Ideas on the Recent Sell-Off
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology: Sparks a Much Needed Boost for Gene Therapy Stocks
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
How Will the Rubble Bounce, or Ideas on the Recent Sell-Off
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology: Panic Has Created Some Compelling Opportunities on the Long Side
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Read GBT S-1 Page 16, Last Paragraph Prior to Selling bluebird
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 EPS; Looking Ahead to ASH 2015 and Beyond
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Pullback Offers Attractive Entry Points
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology: 2H15 Catalysts For Key Stocks From Our Research Universe
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
T-Cell Therapy Update: Companies Look Ahead to New Generation of TCell Therapies with Technology Enhancement Deals
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
T-Cell Therapy Update: Companies Look Ahead to New Generation of TCell Therapies with Technology Enhancement Deals
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.